Company Disclosure
Financial Highlights - Consolidated H1 2026-27
Revenue from Operations: ₹8,194.20 Lakh
Profit Before Tax: ₹3,590.01 Lakh
Profit After Tax: ₹2,809.85 Lakh
Paid-Up Equity Share Capital: ₹856.84 Lakh
Reserves: ₹26,243.65 Lakh
EPS: ₹32.31
Includes CORIS sales figures of ₹1,780.23 Lakhs and EBITDA loss of ₹331 Lakhs for H1 2026-27. CORIS figures for H1 2025-26 were included only from the date of consolidation (29th August 2025).
Financial Highlights - Consolidated excluding Coris H1 2026-27
Revenue from Operations: ₹6,413.72 Lakh
Profit Before Tax: ₹4,320.96 Lakh
Profit After Tax: ₹3,269.49 Lakh
Paid-Up Equity Share Capital: ₹856.84 Lakh
Reserves: ₹32,307.03 Lakh
EPS: ₹38.16
Molecular Diagnostics Division Performance H1 2026-27
Q2 2026-27 Performance: Revenue from operations of ₹4,502.48 Lakh compared to ₹3,042.83 Lakh in Q2 2025-26, representing 36.1% YoY growth
Includes: Consolidated sales from TRUPCR Europe Limited, Manchester of ₹682.91 Lakh and sales from Coris BioConcept SRL, Belgium of ₹917.4 Lakh
Exports: ₹657.49 Lakh in Q2 2026-27 against ₹497.85 Lakh in Q2 2025-26 (32% growth)
Growth Driver: Seasonal Flu Spike in India resulting in ~₹5.5 Crore sales not present in Q2 2025-26
Coris BioConcept Performance H1 2026-27
Revenue: EUR 1.63M with EBITDA loss of EUR 304K compared to EUR 1.58M with EBITDA loss of EUR 554K in H1 2025-26
Loss Reduction: 45% reduction in losses due to control measures
Historical Trend: Q1 and Q2 are loss making; Q3 and Q4 are profitable due to HAT order supply
HAT Order: Received confirmation for EUR 1.41M order (Belgium Govt. order of EUR 6.0M received February 2024 to be supplied over 4 years)
Sales Composition: 75% AMR products (10% growth), 25% other categories (15% de-growth due to Chinese competition)
Business Outlook and Guidance
MDx Market Position: Approximately 15% market share in India's estimated ₹500-600 Cr Total Addressable Market
Industry Growth: Projected 8%-10% CAGR for MDx industry in India
Company Growth Target: 15%-20% overall growth for FY 2026-27 (domestic and export sales)
Coris Outlook: Expected 10-15% sales growth with slight positive EBITDA for 2026-27
Strategic Initiatives and Developments
Regulatory Progress: Successfully passed IVDR QMS audit; IVDR certification expected in due course (can sell as legacy devices until December 31, 2028)
New Product Launches:
- Launched Rapid Tests for Anti-Microbial Resistance (TRURAPID® RESIST-5 OKNVI, TRURAPID® RESIST ACINETO, TRURAPID® RESIST CTX-M)
- Launched TRUPCR® Skin and Nail Fungus Panel Kit and TRUPCR® Aspergillus Detection & Differentiation Kit
- Developing Lyophilised products in final validation stage
Capacity Utilization: Currently operating at ~65% of installed capacity, with potential to scale during seasonal demand spikes
Sales and Distribution
Sales Models in India:
- Tender Sales: 5-7% of total sales
- Contractual/Reagent Rental Model: 20-25% projected contribution
- Other Supplies: 65-70% of total sales
Credit Policy: Following liberal credit policy resulting in higher debtor levels to sustain competition
Global Presence: Products available in 70+ countries with 200+ customers across Europe, Middle East, APAC, LATAM, and North America
Research and Development
Main Thrust Areas: Development of novel formulations, performance monitoring, improvement in existing products/processes
R&D Team: Well-retained team of scientific professionals including Ph.Ds. and M.Scs.
Product Portfolio: 120+ Molecular Diagnostic Assays developed across qPCR, Lateral Flow, NGS, and Digital PCR technologies
Corporate Development
M&A Strategy: Actively pursuing strategic M&A opportunities in USA and other markets with bigger fund size available post-Coris acquisition
TRUPCR Europe Performance: 27.6% sales growth in Q2 2026-27 versus Q2 2025-26
Certifications and Compliance
ISO 13485:2016 certified by BSI, UK
Licensed by CDSCO, Govt. Of India
IVDR compliant (EU 2017/746)
BSI Group appointed as Notified Body for IVDR conformity assessment
CSR Initiatives
Supporting multiple organizations including Army Wives Welfare Association (AWWA), ARUSHI, Sightsavers, Friends of Tribals Society, Prerna Sewa Trust, Sahara Saksharta, and Cachar Cancer Hospital & Research Centre